
    
      This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial
      which plans to enroll 436 subjects. All subjects enrolled will be randomly assigned to the
      test group (n=218) and the control group (n=218). Subjects in the test group and the control
      group will receive Combo stents and Nano stents respectively.
    
  